Ferring Statement on the COVID-19 (novel coronavirus disease) Pandemic and Reproductive Medicine
Saint-Prex, Switzerland – 2 June, 2020
The health and safety of our patients, our employees and their families are Ferring’s number one priority. Ferring is committed to following appropriate global, regional and local medical authority guidance regarding the COVID-19 (novel coronavirus disease) situation to prevent infection spread and to keep patients, our employees and their families safe.
As the situation is now stabilising in many countries, Ferring is working with investigational sites to restart recruitment or continue our clinical trials in fertility, which were halted in impacted countries in March 2020 due to the pandemic. The restarting of clinic trials is in line with the current positions from scientific societies on patients seeking or undergoing fertility treatment, including from the European Society of Human Reproduction and Embryology (ESHRE) and the American Society of Reproductive Medicine (ASRM).
In addition to policies to protect our employees and prevent infection spread, we have also put in place plans to avoid disruption in manufacturing and ensure continuity of supply of our treatments to doctors and patients around the world. However, we unfortunately cannot rule out a future impact on our business as the situation continues to evolve rapidly.
We remain committed to building families worldwide and continue to work closely with healthcare professionals, patient groups and patients to advance treatment and care in reproductive medicine and maternal health.
Our thoughts are with the people and families affected by COVID-19 around the world, including our patients and those working tirelessly to address the pandemic.